Among 310 patients included in this study, 256 patients without a history of HCC who achieved SVR by DAAs were evaluated for Ang2 at baseline and were followed for >1 year from the initiation of DAA therapy. The gene discussed is ANGPT2; the disease is hepatocellular carcinoma.